Outlook for 2024

Published in the Q1 2024 interim report on 25 April 2024

In 2024, the pharmaceutical distribution market is expected to continue to grow. A continuation of a weak consumer confidence might impact the wholesale market development. The recent overall inflationary environment and related cost pressures may have an impact on Oriola’s profitability.  

Oriola expects the adjusted EBIT, excluding the dose dispensing business in Sweden, for the year 2024 to  increase from the adjusted EBIT for 2023 (EUR 19.5 million).